seriously ......................."Apart from $47 million in cash and an additional $75-million non-dilutive credit facility, Mesoblast will likely need additional capital to finance its late-stage development, the analyst said."
I think we have moved on from this issue.
Mesoblast's Delayed Launches, Teva Split Turn Credit Suisse Bearish, page-3
Add to My Watchlist
What is My Watchlist?
